Agree. From memory, the circumstantial evidence from Historical trials on FTO like dosing on Humans is limited to 5 patients in CCRC. Still better than none. I suppose we are going with 30 patients in stratum 2 EMD AML. Plenty of research information provided by Mason seemed to suggest Zantrene was acting more like an FTO inhibitor rather than an anthracycline. Plenty of preclinical data and synergy data over the last 2 years are also pointing to the same fact. Unlike other diseases, at least for Cancer, side effects have to be pretty bad for it to fail. As @johndprent has pointed out, even Otsuka seems to be happy with the collaborative FTO trial with RAC and they see a good chance of success. We just need Zantrene to be proven in just one cancer indication to be multiples of our current market cap. IMHO.
RAC Price at posting:
$2.91 Sentiment: Buy Disclosure: Held
(20min delay)